Drug Testing: Technologies and Global Markets

SUMMARY

Highlights:

This report:

• Describes product segments including drug testing devices by sample specimen, which includes blood, hair, oral fluid, sweat, and urine
• Offers forecasts by product segment from 2008 through 2013
• Discusses diagnostic technologies discussed including enzyme immunoassays, enzyme multiplied immunoassay techniques, fluorescence polarization immunoassays, radioimmuno-assays, and various chromatography techniques
• Includes information on industry structure and the regulatory environment
• Profiles leading manufacturers of drugs of abuse diagnostics.

SCOPE of report

This report contains:

• An overview of drug abuse trends in terms of various geographic regions as well as drug classes.
• Drug abuse statistics in key regions.
• Analysis of regulatory environments in North, South and Central America, Europe, and Asia Pacific, and country-wise summaries of national legislation and policies.
• Drug of abuse testing markets with respect to testing approaches and sample matrices.
• Technology trends in the drug of abuse testing market.
• Leading players in the market and their key products.
• Sales projections through 2014 for drug of abuse testing markets by sample matrix and geographic regions.
• Analysis of leading companies and their successful strategies.

METHODOLOGY

The base year of this study is 2007. Market figures are based on the revenues at the manufacturer's level and are projected at 2007 dollar value (i.e., inflation is not computed into the projection figures). Forecasts are mainly based on the projections of the marketers. Growth of competing products, technologies, drug of abuse growth trends, government policies, and trends in the in vitro diagnostics (IVD) market have also been considered for estimating the future growth trends.

Data to prepare this study was derived from regulatory agencies, trade literature, patient support groups, and annual reports of companies and industry related databases. In addition, discussion with product managers of diagnostic companies, research executives, academic researchers, and government agency spokespersons have been conducted for gaining insights about the market, strategies, and future trends.

INFORMATION SOURCES

The information and analysis presented in this report are based on an extensive survey of the DOA industry as well as a detailed examination of published literature and reports obtained from regulatory authorities, medical research institutions, trade associations, and national and world health organizations. Key information from the literature was used to obtain expert opinions on commercial potential and market sizes from industry professionals.

TABLE OF CONTENTS

Chapter- 1: SUMMARY

• SUMMARY TABLE GLOBAL DRUGS OF ABUSE TESTING MARKET FORECAST, BY REGION, THROUGH 2014 ($ MILLIONS)
• SUMMARY FIGURE GLOBAL DRUGS OF ABUSE TESTING MARKET FORECAST BY REGION, 2006- 2014 ($ MILLIONS)

Chapter- 2: OVERVIEW

• DRUG ABUSE TESTING
• INTRODUCTION
• INTERNATIONAL DRUG TRAFFICKING AND ILLICIT DRUG USE TRENDS BY DRUG TYPE
  • TABLE 1 NUMBER OF ILLICIT DRUG USERS GLOBALLY, 2003- 2007 (MILLIONS)
  • TABLE 2 GLOBAL DRUG SEIZURES BY COUNTRY, DRUG TYPE, AND QUANTITY, JANUARY- JUNE, 2007
  • TABLE 2 (CONTINUED)
  • TABLE 2 (CONTINUED)
• Amphetamine-Type Stimulants Market
• Cannabis Market
• Coca/Cocaine Market
  • TABLE 3 GLOBAL ILLICIT CULTIVATION OF COCA/COCAINE, 2000- 2007 (MT)
• Opium/Heroin Market
  • TABLE 4 GLOBAL ILLICIT CULTIVATION OF OPIUM, 2000- 2007 (MT)
• INTERNATIONAL DRUG TRAFFICKING AND ILLICIT DRUG USE TRENDS BY GEOGRAPHIC REGION
• Africa
• Central America and Caribbean
• North America
• South America
• East and Southeast Asia
• South Asia
• West Asia
• Europe
• Oceania
• U.S. DRUGS OF ABUSE STATISTICS
• National Household Survey on Drug Abuse: SAMHSA U.S.
• Survey by Age and Drug Type
  • TABLE 5 DRUG ABUSE STATISTICS IN THE U.S. BY DRUG TYPE (12 YRS AND OLDER), 2005 AND 2006 (THOUSANDS)
• Survey by Age 13
  • TABLE 6 ILLICIT DRUG USE IN LIFETIME AMONG PERSONS 12 YRS AND OLDER IN THE U.S. BY AGE, 2005 AND 2006 (THOUSANDS)
• Survey by Gender and Drug Type 15
  • TABLE 7 TYPES OF ILLICIT DRUG USE IN LIFETIME AMONG PERSONS 12 YRS AND OLDER IN THE U.S. BY GENDER, 2005 AND 2006 (THOUSANDS)
• Survey by Race and Ethnicity 15
  • TABLE 8 ILLICIT DRUG USE IN LIFETIME AMONG PERSONS 12 YRS AND OLDER IN THE U.S. BY RACE AND ETHNICITY, 2005 AND 2006 (THOUSANDS)
  • TABLE 8 (CONTINUED) 16
• Survey by Geographic Divisions and County Types
  • TABLE 9 ILLICIT DRUG USE IN LIFETIME AMONG PERSONS AGED 12 OR OLDER IN THE U.S. BY GEOGRAPHIC DIVISIONS AND COUNTY TYPES 2005 AND 2006 (THOUSANDS)
• Survey by Education and Current Employment Status
  • TABLE 10 ILLICIT DRUG USE IN LIFETIME AMONG PERSONS AGED 12 OR OLDER BY EDUCATION AND EMPLOYMENT, 2005 AND 2006 (THOUSANDS)
  • TABLE 11 U.S. WORKFORCE ANNUAL DRUGS OF ABUSE POSITIVITY RATE, 1990- 2003 (%)
• DRUGS OF ABUSE STATISTICS, AUSTRALIA
  • TABLE 12 PROPORTION OF AUSTRALIAN POPULATION USING ILLICIT DRUGS AGED 14 YEARS AND OVER BY DRUG TYPE, 1995-2007 (%)
• DRUGS OF ABUSE STATISTICS, CENTRAL ASIA
  • TABLE 13 DRUG ABUSE STATISTICS IN CENTRAL ASIA, 2006

Chapter- 3: DRUGS OF ABUSE TESTING PRACTICES

• SINGLE VS MULTI-PARAMETER TEST
• DOA SCREENING
• CONFIRMATION TESTING
• URINE TESTS
• OTHER TESTING METHODS
• BLOOD TESTING
• ORAL FLUID TESTING
• SALIVA TESTING
• SWEAT TESTING
• HAIR TESTING
• TESTING LOCATIONS
• LABORATORY-BASED DAT
• Criminal Justice
• Police
• Prisons
• Probation
• Workplace Screening
• Military
• Customs and Excise
• Education
• POINT OF CARE DATS
  • TABLE 14 ADVANTAGES AND DISADVANTAGES OF POINT OF CARE TESTING
• ONSITE TESTING VS LABORATORY TESTING
  • TABLE 15 MAJOR ADVANTAGES AND DISADVANTAGES OF ONSITE TESTING
• SAMPLE TYPES FOR LABORATORY TESTING
• URINE TESTING
• HAIR TESTING
• SALIVA/ORAL FLUID TESTING
• BLOOD TESTING
• SWEAT TESTING
• EYE REFLEX
• DETECTION PERIOD
  • TABLE 16 DETECTION PERIODS FOR VARIOUS TYPES OF DRUG TESTING
• FOOLING A DRUG TEST
• FOOLING URINE TESTING
  • TABLE 17 COMMON PARAMETERS TESTED FOR URINE SPECIMEN VALIDITY 33
  • TABLE 18 SOME OF THE COMMERCIAL/COMMON ADULTERANTS USED IN FOOLING URINE TESTS AND THEIR EFFECTS
  • TABLE 18 (CONTINUED)
• FOOLING HAIR TESTING
• FOOLING SALIVA TESTING
• SAMPLE VALIDITY TESTS
  • TABLE 19 URINE SAMPLE VALIDITY TEST METHODS
  • TABLE 19 (CONTINUED)
• FALSE POSITIVES AND FALSE NEGATIVES
• FALSE POSITIVES
  • TABLE 20 CROSS REACTANTS THAT CAN LEAD TO FALSE POSITIVES IN DOA TESTING
  • TABLE 20 (CONTINUED)
• FALSE NEGATIVES
• TESTING TECHNOLOGIES
• IMMUNOASSAYS
• ENZYME IMMUNOASSAY (EIA)
• ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA)
• ENZYME MULTIPLIED IMMUNOASSAY TECHNOLOGY
• FLUORESCENCE POLARIZATION IMMUNOASSAY (FPIA)
• RADIOIMMUNOASSAY (RIA)
• CHROMATOGRAPHY
• Gas Chromatography (GC)
• High Performance Liquid Chromatography (HPLC)
• Thin-Layer Chromatography (TLC)
• Mass Spectrometry (MS)
• Capillary Electrophoresis (CE)
• Hyphenated MS/Chromatography
• Gas-Chromatography-Mass Spectrometry
• EYE REFLEX MEASUREMENTS
• Eye Reflex Measurements (Continued)

Chapter- 4: GOVERNMENT REGULATIONS: DRUG TRAFFICKING AND DRUG ABUSE TESTING

• NORTH AMERICA
• NATIONAL LEGISLATION AND POLICY
• Canada
• Drug Free Workplace
• Mexico 46
• The United States
• Drug-Free Workplace
  • TABLE 21 U.S. DRUG TESTING LEGISLATIONS BY STATE, 2008
  • TABLE 21 (CONTINUED)
  • TABLE 21 (CONTINUED)
  • TABLE 21 (CONTINUED)
  • TABLE 21 (CONTINUED)
• U.S. Department of Transportation
• Drug Testing in the Military
• SOUTH AMERICA
• NATIONAL LEGISLATION AND POLICY
• Bolivia
• Brazil
• Drug-Free Workplace
• Colombia
• Ecuador
• Guyana
• Paraguay
• Peru 56
• CENTRAL AMERICA AND THE CARIBBEAN
• NATIONAL LEGISLATION AND POLICY
• Costa Rica
• Cuba
• El Salvador
• Guatemala
• Haiti
• Jamaica
• Nicaragua
• Panama
• Tegucigalpa
• The Bahamas
• The Netherlands Antilles
• Trinidad and Tobago
• EUROPE
• NATIONAL LEGISLATION AND POLICY
• Bosnia and Herzegovina
• Denmark
• France
• Germany
• Italy
• Latvia
• Norway
• Romania
• Sweden
• Switzerland
• The Netherlands
• The United Kingdom
• DRUG-FREE WORKPLACE POLICY AND LEGISLATION BY EUROPEAN COUNTRY
  • TABLE 22 DRUG-TESTING LEGISLATION BY EUROPEAN COUNTRY, 2008
  • TABLE 22 (CONTINUED)
  • TABLE 22 (CONTINUED)
  • TABLE 22 (CONTINUED)
• ASIA PACIFIC
• NATIONAL LEGISLATION AND POLICY
• Australia
• Bangladesh
• Bhutan
• Cambodia
• Hong Kong
• India
• The NDPS (Regulation of Controlled Substances) Order, 1993
• Japan
• Maldives
• Myanmar
• Nepal
• New Zealand
• Singapore
• South Korea
• Sri Lanka
• Taiwan
• Thailand
• Vietnam

Chapter- 5: GLOBAL DRUGS OF ABUSE TESTING MARKET BY SAMPLE MATRIX

• DRUGS OF ABUSE TESTING SALES 77
  • TABLE 23 GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY SAMPLE MATRIX, THROUGH 2014 ($ MILLIONS)
  • FIGURE 1 GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY SAMPLE MATRIX, 2006- 2014 ($ MILLIONS)
• GLOBAL SALES OF DRUGS OF ABUSE TESTING BY URINE
  • TABLE 24 GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY URINE, THROUGH 2014 ($ MILLIONS/%)
  • FIGURE 2 GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY URINE, 2006- 2014 ($ MILLIONS)
  • TABLE 25 GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY URINE: LABORATORY BASED VERSUS ONSITE, THROUGH 2014 ($ MILLIONS)
  • FIGURE 3 GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY URINE: LABORATORY BASED VERSUS ONSITE, 2007 (%)
• GLOBAL SALES OF DRUGS OF ABUSE TESTING BY BLOOD
  • TABLE 26 GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY BLOOD, THROUGH 2014 ($ MILLIONS/%)
  • FIGURE 4 GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY BLOOD, 2006- 2014 ($ MILLIONS)
• GLOBAL SALES OF DRUGS OF ABUSE TESTING BY ORAL FLUID
  • TABLE 27 GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY ORAL FLUID, THROUGH 2014 ($ MILLIONS/%)
  • FIGURE 5 GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY ORAL FLUID, 2006- 2014 ($ MILLIONS)
  • TABLE 28 GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY ORAL FLUID: LABORATORY BASED VERSUS ONSITE, THROUGH 2014 ($ MILLIONS)
  • FIGURE 6 GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY ORAL: LABORATORY BASED VERSUS ONSITE, 2006 AND 2014 (%)
• GLOBAL SALES OF DRUGS OF ABUSE TESTING BY HAIR
  • TABLE 29 GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY HAIR, THROUGH 2014 ($ MILLIONS/%)
  • FIGURE 7 GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY HAIR, 2006- 2014 ($ MILLIONS)
• GLOBAL SALES OF DRUGS OF ABUSE TESTING BY SWEAT
  • TABLE 30 GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY SWEAT, THROUGH 2014 ($ MILLIONS/%)
  • FIGURE 8 GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY SWEAT, 2006- 2014 ($ MILLIONS)
• GLOBAL SALES OF DRUGS OF ABUSE TESTING BY OTHER SAMPLE MATRICES
  • TABLE 31 GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY OTHER SAMPLE MATRICES, THROUGH 2014 ($ MILLIONS/%)
  • FIGURE 9 GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY OTHER SAMPLE MATRICES, 2006- 2014 ($ MILLIONS)

Chapter- 6: WORLDWIDE INDUSTRY STRUCTURE

• REGIONAL ANALYSIS
  • FIGURE 10 DRUGS OF ABUSE TESTING MARKETS BY GEOGRAPHIC REGIONS, 2007 (%)
  • FIGURE 10 (CONTINUED)
• TOTAL DOA TESTING AND DRUG MONITORING MARKETS AND FORECASTS
  • TABLE 32 GLOBAL DRUGS OF ABUSE TESTING MARKET FORECAST, THROUGH 2014 ($ MILLIONS/%)
  • TABLE 33 DRUGS OF ABUSE TESTING BY LABORATORY, ONSITE, AND HOME TESTING MARKET FORECAST, 2006- 2014 ($ MILLIONS/%)
• GROWTH TRENDS - LABORATORY BASED AND ONSITE DOA TESTING MARKETS
• LABORATORY-BASED DOA TESTING MARKETS AND FORECASTS
  • TABLE 34 DRUGS OF ABUSE TESTING MARKET FORECAST FOR LABORATORY-BASED TESTING, 2006- 2014 ($ MILLIONS/%)
• ONSITE DOA TESTING MARKETS AND FORECASTS
  • TABLE 35 DRUGS OF ABUSE TESTING MARKET FORCAST FOR ONSITE TESTING, THROUGH 2014 ($ MILLIONS/%)
• COMPETITIVE ANALYSIS
  • TABLE 36 MOST NOTABLE MERGERS AND ACQUISITIONS IN THE DOA TESTING MARKETS, 2000- 2007
• Key Market Players in the DOA Testing Markets and Their Products
  • TABLE 37 MAJOR COMPANIES AND THEIR PRODUCTS IN THE DOA TESTING MARKET
• LABORATORY-BASED DOA TESTING MARKET SEGMENT
  • TABLE 38 COMPANIES OFFERING LABORATORY-BASED DOA TESTING PRODUCTS
  • TABLE 38 (CONTINUED)
• ONSITE TESTING MARKET SEGMENT FOR DOA
  • TABLE 39 MAIN ONSITE DOA TESTING MARKET PLAYERS AND THEIR PRODUCTS
  • TABLE 39 (CONTINUED)
• COMMON DRUGS OF ABUSE AND MOST POPULAR DEVICES USED FOR TESTING THEM
  • TABLE 40 COMMON DOA AND POPULAR URINE DRUG SCREENING PRODUCTS
  • TABLE 40 (CONTINUED)
• COMPANIES IN THE ORAL FLUID, HAIR, AND SWEAT TESTING SEGMENTS FOR DOA
  • TABLE 41 KEY MARKET PLAYERS OFFERING DOA TESTING PRODUCTS ON ORAL FLUID, HAIR, AND SWEAT SAMPLE MATRICES
• COMPANY PROFILES
• ABBOTT LABORATORIES
• Abbott Hematology - Diagnostics Division
• ACON LABORATORIES, INC.
• AMERICAN BIO MEDICA CORP. (ABMC)
• AVITAR, INC.
• BECKMAN COULTER
• BIO-RAD LABORATORIES, INC
• CONCATENO, PLC
• F. HOFFMANN-LA ROCHE, LTD.
• INVERNESS MEDICAL INNOVATIONS, INC.
• MEDTOX SCIENTIFIC, INC.
• MICROGENICS
• NANOGEN, INC.
• OLYMPUS DIAGNOSTICS SYSTEMS
• ORASURE TECHNOLOGIES, INC.
• SIEMENS MEDICAL SOLUTIONS USA, INC.
• VARIAN, INC.
• Varian, Inc. (Continued)

Chapter- 7: PATENT ANALYSIS

• TABLE 42 U.S. DRUGS OF ABUSE TESTING PATENTS BY ASSIGNEE, 1978- 2007
• TABLE 42 (CONTINUED)
• TABLE 42 (CONTINUED)
• TABLE 42 (CONTINUED)
• TABLE 42 (CONTINUED)

Chapter- 8: APPENDIX

• TABLE 43 GLOSSARY OF COMMON TERMS
• TABLE 43 (CONTINUED)
• TABLE 43 (CONTINUED)
• TABLE 43 (CONTINUED)
• TABLE 43 (CONTINUED)
• TABLE 44 GLOSSARY OF SCIENTIFIC ABBREVIATIONS
• TABLE 45 ASSOCIATIONS